Waters received FDA 510(k) clearance for a home-collection HPV test, according to 360Dx and GenomeWeb. The clearance marks an entry into molecular diagnostics for the company, which is known for liquid chromatography and mass spectrometry platforms serving pharmaceutical, food safety, and environmental testing markets.
The reports did not specify whether the clearance covers the collection device alone or an integrated sample-to-result system. Waters has not disclosed details on the test's underlying technology, pricing, clinical validation data, or commercial launch timeline.
Home-collection HPV testing targets the roughly one-third of eligible U.S. women not up to date on cervical cancer screening. The FDA cleared Roche's cobas HPV self-collection option in 2024. Hologic and BD have also pursued similar regulatory pathways. Self-collection eliminates the need for a clinician-administered pelvic exam, identified as a barrier to screening adherence.
Waters' existing distribution network is oriented toward research and industrial customers, not clinical laboratories or health systems. Commercial uptake in the diagnostics market depends on reimbursement coverage, clinical workflow integration, and laboratory adoption. The company has not publicly addressed its go-to-market strategy or potential partnerships with established diagnostics distributors.
For clinical lab directors, the absence of disclosed sensitivity and specificity figures makes it difficult to assess the test's competitive position against Roche's cobas platform, which published large-cohort data supporting its self-collection claim.